marked.bio

AKT inhibitor · small molecule

ipatasertib

3 active trials across 7 of our biomarkers, targeting AKT. Not approved for any biomarker on marked.bio yet.

Also known as GDC-0068, RG7440.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 1 1 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
MSI-H / dMMR 1 2 Phase 2
PIK3CA activating mutation 1 4 Phase 1/2
ALK fusion 0 1 –
BRAF V600E 0 1 –
RET fusion or mutation 0 1 –

Trials

3 of 6 trials shown

  1. Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

    Recruiting Phase 2 German Cancer Research Center Started 2023Primary completion 2030-03 NCT05332561

    atezolizumabinavolisibipatasertibolaparibsacituzumab govitecantrastuzumabpertuzumab

    Arm 6 (Trastuzumab / Pertuzumab, ERBBB): HER2 exon-20 insertion, Activating HER2-mutation

    HER2 (ERBB2) activating mutationBRCA1/2 mutationEarly-stage Breast Cancer

  2. A Trial of Ipatasertib in Combination With Atezolizumab

    Active, not recruiting Phase 1/2 Institute of Cancer Research, United Kingdom Started 2018Primary completion 2026-03 NCT03673787

    ipatasertibatezolizumab

    …other aberrations predicted to result in a hyperactivated PI3K-AKT pathway (eg activating mutations in PIK3CA, AKT1, AKT2) or PTEN loss (assessed by immunohistochemistry (IHC) (n=12).

    PIK3CA activating mutationSolid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic

  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2015Primary completion 2027-12 NCT02465060

    adavosertibafatinibbinimetinibcapivasertibcopanlisibcrizotinibdabrafenibDasatinibdefactiniberdafitinibfexagratinibipatasertib

    …candidate for Z1M based on local Clinical Laboratory Improvement Act (CLIA) assessment of mismatch repair deficiency (MMRd) by immunohistochemistry (IHC) or microsatellite instability (MSI) status by polyme…

    MSI-H / dMMRAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma